Daclizumab: outcome of phase III trials and mechanism of action

Publisher Website

1 August 1998

journal article
Published by Elsevier in Transplantation Proceedings

Vol. 30 (5) , 2155-2158
https://doi.org/10.1016/s0041-1345(98)00571-5

Abstract

No abstract available

This publication has 4 references indexed in Scilit:

A PHASE I TRIAL OF HUMANIZED ANTI-INTERLEUKIN 2 RECEPTOR ANTIBODY IN RENAL TRANSPLANTATION1
Transplantation, 1997
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION
Transplantation, 1995
A RANDOMIZED PROSPECTIVE TRIAL OF ANTI-TAC MONOCLONAL ANTIBODY IN HUMAN RENAL TRANSPLANTATION
Transplantation, 1991
Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal Allografts
New England Journal of Medicine, 1990